"Lab-on-a-Chip" Can Detect Lung Cancer Early
the Cancer Therapy Advisor take:
According to a new study published in the journal Royal Society of Chemistry, researchers at the University of Kansas in Lawrence, Kansas, have developed a "lab-on-a-chip" that can detect lung cancer much earlier than an invasive biopsy with only a small drop of blood.
The a "lab-on-a-chip" device uses microfluid technology that will analyze the nucleic acids and proteins in certain exosomes, small vesicles of molecules that cells release. Their device has already been successfully tested on lung cancer.
The "lab-on-a-chip" device uses smaller samples and is cheaper, faster, and more sensitive than a traditional instruments used in a laboratory. Unlike breast and colon cancer, lung cancer does not have a widely used screening tool, and most cases of lung cancer are diagnosed after invasive biopsies. This blood test is noninvasive, inexpensive, and more sensitive, and would be an effective screening tool for a large population to detect early-stage lung cancers.
The researchers have tested the device in both lung and ovarian cancer, and hope to test it in other cancers as well. The team has received funding from the National Cancer Institute to further develop the device.
Chip can detect lung cancer much earlier than an invasive biopsy with only a small drop of blood.
At present, diagnosis of lung cancer relies on an invasive biopsy that is only effective after tumors are bigger than 3 cm or even metastatic. Earlier detection would vastly improve patients' chances of survival. Now a team of researchers is developing a "lab-on-a-chip" that promises to detect lung cancer - and possibly other deadly cancers - much earlier, using only a small drop of a patient's blood.
In the Royal Society of Chemistry journal, Yong Zeng, assistant professor of chemistry at the University of Kansas, and colleagues report a breakthrough study describing their invention.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia